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Abstract
Drug administration through the nose offers great possibilities which have been discovered in the past few decades. Besides the most 
known local effect, systemic and central nervous system effect is also available, the administration is non-painful and the degradation 
effect of the gastrointestinal tract can be avoided. Amongst the nasal formulations, powders have become more popular as their stability 
is favorable compared to the liquid formulations and a higher doses can be administered in powder form. The quality insurance and 
stability of the products in the pharmaceutical field have gained considerable attention in the last decades. Due to this fact, the aim was 
to execute a long-term stability study of a previously developed, nanosized lamotrigine (LAM) containing nasal powder (NP) formula-
tion. The results of the stability test showed that the NP formulation preserved its key properties (particle size, morphology, structure 
and in vitro drug release) after 6 months of storage.
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1. Introduction
The nose offers a great possibility to avoid adverse 
events and increase patient compliance[1–4]. Due 
to its advantageous properties local, systemic and 
central nervous (CNS) system effects are also 
available [5–7]. The application of innovative and 
efficient products, that are containing nanoparti-
cles, may lead to the improvement of different 
therapies [8,9]. The quality insurance of pharma-
ceutical products has received considerable atten-
tion in the past few years. That is why the stability 
of the formulations has become extremely impor-
tant and therefore, quality influencing parameters 
need to be kept constant during the transport, 
storage, and application. Generally, solid dosage 
forms (e.g. nasal powders) have better stability 
than liquid formulations [10–12].
In our previous studies, a nanosized lamotrigi-
ne (LAM) containing nasal powder (NP) product 
was researched and developed. The investigations 
of the product showed that due to the effect of 
milling, the nanosized LAM particles became 
partly amorphous and distributed homogenously 
on the polymer, polyvinyl alcohol (PVA) matrix. 
Moreover, the product performed rapid and high 
amount of drug release in vitro and in vivo. This 
study aimed to carry out the long-term stability 
study of the previously developed NP formula-
tion, which contained nanosized LAM [13–15].
2. Materials and methods
2.1. Materials
Lamotrigine, poorly water-soluble (0.17 mg/mL at 
25 °C) was purchased from Teva Ltd. (Budapest, 
Hungary). PVA (Mw = 27,000), water-soluble syn-
thetic polymer – that was applied to stabilize the 
unique drug particles, thus improving their ab-
sorption – was supplied by ISP Customer Service 
GmBH (Cologne, Germany).
2.2. Sample Preparation
PVA was used as an additive during the sample 
preparation process to maintain the stability and 
individuality of LAM particles. NP sample was 
produced as follows: 0.8 g PVA and 1 g LAM were 
mixed in a Turbula mixer (Turbula System Schatz; 
Willy A. Bachofen AG Maschinenfabrik, Basel, 
Switzerland) using 60 rpm for 10 min. After mix-
ing, the sample was placed into a planetary ball 
mill (Retsch PM 100; Retsch, Neuhausen, Germa-
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ny) and milled in a 50 mL capacity milling cham-
ber for 1.5 h on 400 rpm with 10 steel balls (diame-
ter 10 mm, the weight of each ball 4.02 g). In the 
case of the physical mixture (PM), PVA was milled 
for 1.5 h on 400 rpm and then—according to our 
previous experiments—it was mixed with un-
milled LAM using the same Turbula mixer for 10 
min on 60 rpm.
2.3. Circumstances of the stability
Stability tests were performed according to the 
ICH Q1A guideline [16] in Binder KBF 240 (Bind-
er GmbH, Tuttlingen, Germany) equipment, with 
a constant-climate chamber. An electronically 
controlled APT.lineTM line preheating chamber 
and refrigerating system ensured temperature 
accuracy and reproducibility of the results in the 
temperature range between 10 and 70 °C and the 
relative humidity (RH) range between 10 and 
80%. The stability test was performed at 25 ± 2 °C 
with 50 ± 5% RH (room conditions). Samples 
were kept in a closed jar during the tested peri-
od. Sampling was carried out after 1 day; 3 and 6 
months.
2.4. Particle size and morphology characterization
The particle size of the microparticles was charac-
terized by using Leica Image Processing and 
Analysis System device (Leica Q500MC; Leica Mi-
crosystems, Wetzlar, Germany). The test parame-
ters of 300 particles were their length, width, area, 
and district/convex perimeter.
The morphology and the size the LAM nano-
particles – that were on the surface of the polymer 
microparticles – were investigated by SEM (Hita-
chi S4700; Hitachi Ltd., Tokyo, Japan) at 10 kV. 
The samples were gold–palladium-coated (90 s) 
with a sputter coater (Bio-Rad SC502; VG Micro-
tech, Uckfield, UK) using an electric potential of 
2.0 kV at 10mA for 10 min. The air pressure was 
1.3–13.0 mPa. Distribution of LAM particle diame-
ter was obtained by analyzing SEM images with 
the ImageJ software (1.50i; Java 1.6.0_20 [32-bit]; 
Windows NT) environment using approximately 
500 particles [17]. 
Statistical analysis was performed with TIBCO 
Statistica® 13.4 (Statsoft Hungary, Budapest, Hun-
gary). All reported data are means ± SD. The Stu-
dent’s t-test was used to determine the statistical 
significance. Changes were considered statistically 
significant at p < 0.05.
2.5. Structural investigations
2.5.1. Thermoanalytical measurements
The Mettler Toledo TGA/DSC 1 thermal analysis 
system (Mettler-Toledo GmbH, Greifensee, Swit-
zerland) was applied to characterize the struc-
tures of the products. The DSC (differential scan-
ning calorimetry) and TG (thermogravimetry) 
measurements were made by examining approxi-
mately 3-5 mg of samples in the temperature 
range between 25 ˚C and 230 ˚C at a heating rate of 
5 °C/min under constant argon flow of 150 mL/min 
and nitrogen flow of 50 mL/min. Data analysis 
was performed using the STARe software (Met-
tler-Toledo GmbH, Greifensee, Switzerland). The 
cristallinity indexes were calculated based on the 
ratio Normalized integrals, where the PM samples 
was considered as 100%.
2.5.2. X-ray powder diffraction (XRPD)
The XRPD measurement was carried out with a 
BRUKER D8 advance X-ray powder diffractome-
ter (Bruker AXS GmbH, Karlsruhe, Germany) 
with Cu K λI radiation (λ=1.5406 Å) and a VÅN-
TEC-1 detector (Bruker AXS GmbH, Karlsruhe, 
Germany). The powder samples were loaded in 
contact with a plane quartz glass sample slide 
with an etched square and measured. Samples 
were scanned at 40 kV and 40 mA. The angular 
range was 3°–40° 2θ, at a step time of 0.1 seconds 
and a step size of 0.007°. All manipulations, in-
cluding Kα2 stripping, background removal and 
smoothing of the area under the peaks of the dif-
fractograms, were performed using the DIF-
FRACplus EVA software. The crystallinity index 
(Xc) values were calculated based on the follow-
ing formule, where A marks the area under the 
whole curve:
Xc= Acrystalline/ (Acrystalline + Aamorphous) *100
PM sample was considered as 100%.
2.6. In vitro release study
The modified paddle method (USP dissolution ap-
paratus, type II; Pharma Test, Hainburg, Germa-
ny) was used to examine the dissolution rate of 
LAM-containing co-milled nasal powders and de-
termine the drug release profile from the samples. 
The test was carried out under nasal conditions 
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for temperature and pH. 100 ml phosphate-buff-
ered saline solution (PBS of pH 5.60 at 30 °C) was 
used as a medium in 150 mL vessels, in which 108 
mg of the samples were tested. The paddle was 
placed to halfway through the medium and was 
rotated at 50 rpm, and the sampling points were at 
5 min, 10 min, 15 min, 30 min, 45 min, and 60 min. 
In each sampling point 2 mL samples were taken, 
which volume was immediately replaced with 
fresh buffer solution to maintain the permanent 
volume. Cellulose ester membranes with 0.45 µm 
pore diameter was used for filtration. The sam-
pling points were more frequent in the beginning 
of the investigation as the mucociliary clearance 
renews the mucus every 15 min. The following 
sampling points offered extra information about 
the dissolution behavior of LAM. After filtration, 
the drug content of the aliquots was determined 
using spectrophotometry (Unicam UV/VIS Spec-
trophotometer) at 307 nm. The tests were carried 
out in triplicates.
3. Results and discussion
3.1. Characterization of particle size and morphology
The results of particle size determination resulted 
in same particle size of the product during the ex-
amined period (Table 1), which 
shows that the product’s particles 
did not aggregate. The size falls 
into the range which is desired in 
the case of nasal powders, which 
is 10-40 µm [17].
The particle size of LAM in the 
formulation showed an increase 
with relatively high standard de-
viation, which is related to the na-
noscale range and the ImageJ 
technique used (Table 2). However, according to re-
sults of the statistical analysis there is no signifi-
cant difference in the particle sizes during the stor-
age period, thus the previously experienced rapid 
and high degree of release can be predicted.
The SEM pictures confirm the results of the particle 
size determination as the nanosized LAM particles can 
be seen on the PVA surface in a homogenous distribu-
tion and showed no sign of aggregation during the test-
ed period (Figure 1). 
3.2. Structural investigations
The DSC curves (Figure 2A) in the tested period 
shows that the partly amorphous property of the 
sample did not change considerably. The melting 
point of LAM was between 216 °C and 217 °C, 
which became lower (~ 204 °C) due to the effect of 
milling and the presence of PVA. The two melting 
points merged as LAM melted on ~204 °C, while 
PVA did it on ~210 °C. However, the character and 
area of the endothermic peak are almost the same 
in each sampling point in the case of the NP for-
mulation. Compared to the PM, which was re-
garded as 100%, the crystallinity degrees of the 
samples were between 42 and 48%.
This immutability can be seen in the case of 
XRPD diffractograms (Figure 2B). According to the 
Table 1 The results of particle size investigation of the product. 
Average size of the product (µm) t-value p-value Significance
1-day 29.91±15.85 -0.1435 0.8883 n.s.
3 months 28.48±12.81 0.2994 0.7690 n.s.
6 months 26.52±11.14 0.9064 0.3801 n.s.
In the table n.s means that there is no significant difference at 95% level.
Table 2 The results of particle size investigation of LAM. 
Average size of LAM (nm) t-value p-value Significance
1-day 97±60 1.2382 0.2347 n.s.
3 months 105±77 0.7934 0.4408 n.s.
6 months 120± 84 -0.0408 0.9687 n.s.
In the table n.s means that there is no significant difference at 95% level.
Figure 1 The SEM pictures of the NP samples
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diffractograms, the characteristic 
2θ° values of the raw LAM were 
at 12.57, 19.62, 27.04, 27.19 and 
28.92 [13], which can be also seen 
in the case of the PM. Due to the 
co-milling with PVA, the crystal-
linity of the LAM decreased as the 
intensity of the characteristic 
peaks decreased in the 1-day sam-
ple. After 6 months, this de-
creased crystallinity was main-
tained. The crystallinity index 
was found 47.58% in the 1-day 
sample, which value did not 
change considerably during the 
storage. 
Table 3 shows the crystallinity 
index values of the samples. The 
results of the measurement con-
firmed the DSC results, which 
means that the LAM became and 
remained partly amorphous due 
to the milling effect and the pres-
ence of PVA in the tested period. 
Moreover, the TG results showed 
no change in mass, which refers 
that no dehydration or decompo-
sition occurred during the investi-
gation.
3.3. In vitro release study
In Figure 3, it can be seen that the 
LAM from the surface of the poly-
mer released rapidly in a high 
amount in the case of the NP 
sample compared to the PM and 
raw LAM. This rapid release was 
maintained during the examined 
period as practically there is no 
difference between the samples. 
The rapid dissolution rate was oc-
curred due to the nanosized prop-
erty of LAM and the presence of 
PVA.
4. Conclusion
To conclude the study, it can be said that the key 
properties of the NP product did not change con-
siderably. The particle size of the product did not 
show relevant change during the tested period, 
while the particle size of LAM in the formulation 





6 months 47.53 48.40
Figure 2 The DSC curves (A) and the XRPD diffractograms (B) of the samples
Figure 3 The results of the release study, where LAM is the raw lamotrigine and 
PM is the Physical Mixture
A
B
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showed an increase with no significant difference. 
Moreover, the partly amorphous property of LAM 
was maintained during the stability test and ac-
cording to the TG results, no dehydration or de-
composition occurred, which suggests that the 
sample did not remove water from its surround-
ings during storage. The results of the dissolution 
studies showed a rapid and high amount of the re-
leased drug in the examined period. The results 
predict that PVA could prevent the particles from 
aggregation and recrystallization. However, fur-
ther stability investigations are required – accord-
ing to ICH guidelines –, but it they will be worth 
carrying out in a final package. According to this 
study, it is predictable that the product can main-
tain its quality over a long period and thus to pro-
duce a proper effect.
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